Prevalence, clinical course and treatment of chronic gastritis at the present stage

Main Article Content

G.V. Osyodlo
Y.Y. Kotyk
M.A. Kalashnikov
V.V. Osyodlo


Background. The importance of the problem of chronic gastritis (CG) is determined by its high proportion in the structure of gastrointestinal pathology, reduced quality of life of patients, and possible complications. The study aimed at the investigation of the incidence and features of the clinical course of CG in servicemen at the present stage and pharmacoeconomic efficacy of bismuth and triple anti-helicobacter therapy (AHBT) in H. pylori (HP) — associated erosive gastritis with the use of domestic drugs. Materials and methods. At the first stage, the indicators of the admission rate of servicemen with CG and the peculiarities of the endoscopic picture of the gastric mucosa were analyzed. At the second stage, the features of the clinical course were studied and a pharmacoeconomic analysis of treatment regimens in servicemen with HP-associated erosive gastritis with proton pump inhibitors of different generations and domestic bismuth subcitrate, used in triple and bismuth-containing regimens, was performed. Results. An epidemiological, clinical, and pharmacoeconomic analysis of HP-associated CG in servicemen at the present stage has been conducted. It is reasonable to treat servicemen with HP-associated erosive gastritis with domestic drugs using bismuth-containing anti-helicobacter therapy, which will improve the efficiency and quality of treatment and avoid unjustified budget costs. Conclusions. Among the servicemen of the Armed Forces of Ukraine, starting from 2013, there is a tendency to increase the number of erosive gastroduodenal lesions with a predominant lesion of the antrum of the stomach. Pharmacoeconomic analysis of the treatment of HP-associated erosive gastritis showed the feasibility of switching to bismuth-containing AHBT with the use of domestic rabeprazole and bismuth subcitrate. This is justified by a higher anti-Helicobacter activity by 1.2 times (20 %), 1.6 times better (60 %) cost-effectiveness, and 1.4 times higher (40 %) cost-utility.

Article Details

How to Cite
Osyodlo, G., Kotyk, Y., Kalashnikov, M., & Osyodlo, V. (2021). Prevalence, clinical course and treatment of chronic gastritis at the present stage. GASTROENTEROLOGY, 55(2), 74–80.
Original Researches


Gerasymova OO, Ovsienko YeV. The results of VEN/frequency analysis of pharmacotherapy of patients with chronic gastroduodenitis in a healthcare institution of Kharkiv. Social pharmacy in health care. 2018;4(2):70-75. doi:10.24959/sphhcj.18.112. (in Ukrainian).

Gradov AP, Grinevich VB. Conceptual bases of definition of medico-economic efficiency of medical processes. Gedeon Richter in CIS. 2000;(3):5-9. (in Russian).

Os’odlo GV, Goncharov JaP, Besaga VV, et al. Clinical and epidemiological analysis of gastrointestinal pathology in ATO participants. Military medicine of Ukraine. 2015;15(1):41-45. (in Ukrainian).

Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi:10.1136/gutjnl-2016-312288.

Ol'hova IV, Trohymchuk VV. Pharmacoeconomic aspects of chronic gastritis and duodenitis in children. Ukrainian Medical Almanac. 2014;17(1):97. (in Ukrainian).

Stepanov YuM, Mosiichuk LM. The role of bismuth in the treatment of gastroduodenal pathology (literature review and own researches). Gastroenterologìa. 2016;(61):9-17. doi:10.22141/2308-2097.3.61.2016.79151. (in Ukrainian).

Stepanov YuM. Digestive diseases and gastroenterological care for the population of Ukraine: achievements, problems and solutions. Zdorov’ja Ukrai'ny. Gastroenterologija. Gepatologija. Koloproktologija. 2014;(33):10-11. (in Ukrainian).

Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep;64(9):1353-1367. doi:10.1136/gutjnl-2015-309252.

Iakovlievа LV, Bezditko NV, Gerasymova OO, et al. Farmakoekonomika: navchal'nyj posibnyk dlja studentiv VNZ [Pharmacoeconomics: a textbook for university students]. Vinnytsya: Nova knyga; 2009. 208 р. (in Ukrainian).

Fadieienko GD, Nikiforova YaV, Cherelyuk NI. The ways of antihelicobacter therapy in Ukraine (based on the data of analysis of the Ukrainian Registry Hp-EuReg - UKRAINE). Zdorov'ja Ukrai'ny. Gastroenterologija. Gepatologija. Koloproktologija. 2018;(50):27-28. (in Ukrainian).

McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012 Sep;36(5):414-425. doi:10.1111/j.1365-2036.2012.05211.x.